Advances in the treatment of heart diseases: A review of emerging therapies

Cardiovascular diseases (CVDs) remain the leading cause of mortality in Brazil. In 2022, approximately 400,000 deaths were attributed to these diseases, regaining the top position after the COVID-19 pandemic in 2021. The increasing prevalence of cardiovascular diseases (CVDs) has driven several sectors to invest in research and technological innovations aimed at human health. Pharmaceutical industries and biotechnology companies have played a crucial role in developing advanced therapies and innovative solutions to mitigate the impact of these diseases on the global population. This study aims to highlight the main innovations implemented as well as new strategies in the management of CVDs, aiming to demonstrate their effect in reducing prevalence, consequences, and impact on global population quality of life. This study was conducted through a narrative review of the literature, using the following sources: scientific databases: PubMed, LILACS, and Google Scholar; documents from official bodies: Brazilian Ministry of Health, World Health Organization (WHO), and other government reports or international medical organizations; clinical guidelines: updated recommendations from medical and scientific societies related to the management of CVDs. Modern and emerging strategies in the treatment of cardiovascular diseases (CVDs) have led to notable advances, particularly in three key areas: diagnostic technologies, pharmacological therapies, and minimally invasive interventions. Each of these areas contributes significantly to improving clinical management, providing more effective, safer, and personalized treatments for patients. As research continues to advance, new therapies and emerging approaches, such as gene and cell therapy, offer a promising future for the treatment of heart diseases, improving survival and quality of life for patients worldwide.